Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1990 3
1991 2
1992 1
1993 4
1994 3
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
Takesue BY, Pyle JM, Mokyr MB. Takesue BY, et al. Cancer Res. 1990 Dec 1;50(23):7641-9. Cancer Res. 1990. PMID: 2123740 Free article.
Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
Rubin M, Bluestone JA, Newell KA, Prokhorova A, Mokyr MB. Rubin M, et al. J Immunol. 1994 Apr 1;152(7):3522-9. J Immunol. 1994. PMID: 8144932
Enhancement of the effectiveness of Lyt-2+ T-cells for adoptive chemoimmunotherapy by short-term exposure of tumor-bearer spleen cells to polyethylene glycol and/or melphalan.
Wise JA, Mokyr MB, Dray S. Wise JA, et al. Cancer Res. 1989 Jul 1;49(13):3613-9. Cancer Res. 1989. PMID: 2567207 Free article.
Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB, Rubin M, Newell KA, Prokhorova A, Bluestone JA. Mokyr MB, et al. J Immunol. 1993 Nov 1;151(9):4838-46. J Immunol. 1993. PMID: 8409442
Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM, Barker E, Mokyr MB. Weiskirch LM, et al. Cancer Immunol Immunother. 1990;31(3):129-38. doi: 10.1007/BF01744726. Cancer Immunol Immunother. 1990. PMID: 2337902
Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
Gorelik L, Prokhorova A, Mokyr MB. Gorelik L, et al. Cancer Immunol Immunother. 1994 Aug;39(2):117-26. Cancer Immunol Immunother. 1994. PMID: 8044831
Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas.
Laude M, Siessmann KL, Mokyr MB, Dray S. Laude M, et al. Cancer Res. 1991 Sep 1;51(17):4516-22. Cancer Res. 1991. PMID: 1873795 Free article.
Transforming growth factor-beta-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy.
Weiskirch LM, Bar-Dagan Y, Mokyr MB. Weiskirch LM, et al. Cancer Immunol Immunother. 1994 Apr;38(4):215-24. doi: 10.1007/BF01533512. Cancer Immunol Immunother. 1994. PMID: 8168116
Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy.
Laude M, Russo KL, Mokyr MB, Dray S. Laude M, et al. Cancer Immunol Immunother. 1993;36(4):229-36. doi: 10.1007/BF01740904. Cancer Immunol Immunother. 1993. PMID: 8439986
Presence of an enlarged pool of MOPC-315-specific cytotoxic T lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy.
Bartik MM, Ahn MC, Baumgartel BA, Hendricks RL, Mokyr MB. Bartik MM, et al. Cancer Immunol Immunother. 1990;32(3):143-53. doi: 10.1007/BF01771449. Cancer Immunol Immunother. 1990. PMID: 2289208
16 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback